WorldPress Platform https://releases.worldpressplatform.com/healthcare WorldPress Platform Copyright 2026. All Rights Reserved. WorldPress Platform. Susie White receives San Bernardino County Medical Society President's Award https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare RANCHO CUCAMONGA, Calif., June 30, 2025 /PRNewswire/ -- Inland Empire Health Plan (IEHP) Chief Operating Officer Susie White received the San Bernardino County Medical Society's (SBCMS) 2025 President's Award during its annual Installation of Officers and Award Recognition Dinner in Victorville on June 26. 2025-07-01 10:52:12 Pet King Brands' ZYMOX Designated as a 2025 Vanguard Awards Winner in Eye and Ear Care https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Pet Insight Magazine recognizes ZYMOX as a category trailblazer. 2025-07-01 10:52:03 Coway lanza el Airmega 50, su purificador de aire cilndrico ms compacto hasta la fecha https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare AMSTERDAM, 1 de julio de 2025 /PRNewswire/ -- Coway, la empresa surcoreana lder en tecnologa de bienestar, ha lanzado en el mercado europeo el Airmega 50, el modelo ms compacto de su lnea de purificadores de aire hasta la fecha. Este nuevo lanzamiento aporta una purificacin de aire premium a espacios cotidianos, priorizando la portabilidad, el rendimiento y la tranquilidad. 2025-07-01 10:52:01 HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement with Shanghai Henlius Biotech, Inc. (hereafter "Henlius"). The deal grants Henlius exclusive development and commercialization rights to HCB101 across Greater China (including Mainland China, Hong Kong, and Macau), key Southeast Asian countries, as well as all countries in the Middle East and North Africa (MENA). 2025-07-01 10:51:53 Piramal Pharma Solutions inaugure un plan d'expansion de 90 millions de dollars https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare MUMBAI, Inde, 1er juillet 2025 /PRNewswire/ -- Piramal Pharma Solutions, une organisation de dveloppement et de fabrication sous contrat (CDMO) de premier plan mondial, qui fait partie de Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), a rcemment annonc un plan d'investissement de 90 millions de dollars pour agrandir deux de ses installations amricaines, qui sont essentielles son offre intgre. Cet investissement ambitieux souligne l'engagement de l'entreprise occuper une position de leader dans l'industrie grce une croissance et une innovation continues. Les deux sites concerns par l'extension sont: 2025-07-01 10:51:49 Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare OSLO, Norway, July 1, 2025 /PRNewswire/ -- Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for GLIX1 for the treatment of malignant glioma, a category of devastating brain cancers that includes glioblastoma. 2025-07-01 10:51:42 Pioneering Global Presence, Empowering the World - Zuowei Technology Shining at WHX Miami Medical Expo https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SHENZHEN, China, July 1, 2025 /PRNewswire/ --From June 11 to 13, the 2025WHX Miami Medical Expo (formerly known as FIME), the annual grand event of the medical industry in the Americas, was held at the Miami Beach Convention Center. As one of the largest and most influential professional exhibitions for medical devices and equipment in the Americas, WHX Miami attracted top companies from around the world, serving as a vital hub connecting the healthcare markets of North America, South America, and the Caribbean. Among the many exhibitors, Shenzhen Zuowei Technology Co., Ltd. from China stood out with its impressive presence. Its cutting-edge intelligent nursing robots and innovative solutions became a highlight of the expo, drawing significant attention from attendees and industry professionals alike. 2025-07-01 10:51:40 Vitrolife Group completes refinancing facility backed by leading Nordic Banks https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare GOTHENBURG, Sweden, July 1, 2025 /PRNewswire/ -- Vitrolife AB (publ) has today renewed and signed a loan agreement of EUR 300 million comprising of term loan and revolving credit facility. The term loan will be used to refinance existing debt and the revolving credit facility will be available for general corporate purposes. 2025-07-01 10:51:37 WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SHANGHAI and SINGAPORE, July 1, 2025 /PRNewswire/ -- On June 30, WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the mechanical completion of its manufacturing site atTuas Biomedical Park in Singapore has been successfully achieved. This milestone signifies that this manufacturing site, spanning approximately 25,000 square meters, will now officially transition into the facility C&Q (Commissioning and Qualification) stage. The Singapore site is expected to commence operations by the end of 2025 and Good Manufacturing Practice (GMP) manufacturing in 2026. Upon that, the site will offer comprehensive production capabilities from the preclinical stage to commercialization. 2025-07-01 10:51:34 Camurus' Oczyesa receives marketing authorization for treatment of acromegaly in the EU https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare LUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.1 2025-07-01 10:51:33 Camurus' Oczyesa receives marketing authorization for treatment of acromegaly in the EU https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare LUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.1 2025-07-01 10:51:32 USANA Announces the Elevation of Its Opportunity https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Enhanced incentives, a renewed brand story, and stronger sales system are aimed at driving early success and sustainable growth for USANA Brand Partners 2025-07-01 10:49:19 W Paryu odbyo si wydarzenie promocyjne Climate Challenge (Hainan Baoting) Europe https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Wsparcie wsppracy Chiny-Europa w kierunku zielonej i niskoemisyjnej przyszoci. 2025-07-01 10:49:01 Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system 2025-07-01 10:48:17 Implantica announces publication of the landmark RefluxStop 5-year clinical study results demonstrating excellent long-term success https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare VADUZ,Liechtenstein, July 1, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device RefluxStop, a treatment field with 1 billion sufferers, announces the publication of RefluxStop's extraordinary 5-year clinical data for food passageway-related outcomes in the prestigious journal, Surgical Endoscopy, an official journal of SAGES (American Gastrointestinal and Endoscopic Surgeons) and EAES (European Association For Endoscopic Surgery). 2025-07-01 10:47:23 FAIR PLAY MENARINI INTERNATIONAL AWARD, LUIS FIGO JOINS THE GREAT SPORTS STARS ACKNOWLEDGED IN 2025 https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare FLORENCE, Italy, July 1, 2025 /PRNewswire/ -- Surprises never end when it comes to the Fair Play Menarini International Award: Lus Figo, European football legend and true icon of sporting integrity, will be among the awardees of the 29th edition of the event, taking place on July 2nd and 3rd in Florence and Fiesole. With his charisma, and a career marked by international successes and unwavering respect for the rules, the Portuguese sports star fully embodies the founding values of the Award. 2025-07-01 10:46:31 TRC Healthcare Launches Upgraded NatMed Pro to Further Support Evidence-Based Natural Medicine Use with Smarter Tools https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare DENVER, July 1, 2025 /PRNewswire/ -- TRC Healthcare, the leading provider of evidence-based medication-related resources, announced last week the launch of an upgraded NatMed Pro, the largest unbiased natural medicines database available to healthcare, research, and industry professionals. Built on trusted independent evidence-free from commercial influence-NatMed Pro delivers objective insights clinicians and researchers can trust. The redesigned platform now offers faster performance, mobile access, and seamless data integration. 2025-07-01 10:44:56 Award-Winning Self-Service Registration: DERMALOG Sets New Standards for Security and Efficiency https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare The German Design Council has once again honored outstanding innovations in Berlin. Among the award recipients: DERMALOG Identification Systems GmbH, recognized for its Self Registration Kiosk featuring the integrated all-in-one VF1 scanner - a solution setting new benchmarks for digital security and seamless enrollment processes. 2025-07-01 10:44:54 Enregistrement en libre-service prim : DERMALOG tablit de nouvelles normes en matire de scurit et d'efficacit https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Le Conseil allemand du design a une nouvelle fois rcompens des innovations exceptionnelles Berlin. Parmi les laurats : DERMALOG Identification Systems GmbH pour son kiosque d'enregistrement autonome, quip du scanner multifonction VF1 - une solution qui redfinit les standards de scurit numrique et de simplicit d'inscription. 2025-07-01 10:44:45 Registro autoservicio galardonado: DERMALOG establece nuevos estndares de seguridad y eficiencia https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare El Consejo Alemn de Diseo volvi a premiar en Berln las innovaciones ms destacadas. Entre los galardonados se encuentra DERMALOG Identification Systems por su quiosco de registro autoservicio con el escner todo en uno VF1 integrado, una solucin que marca un nuevo referente en seguridad digital y procesos de registro cmodos. 2025-07-01 10:44:44 Turning the Tide on Obesity, Digestive Diseases and Cancers: EU Urged to Act Now https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare BRUSSELS, June 30, 2025 /PRNewswire/ -- Obesity is fuelling a sharp rise in digestive diseases and cancers across Europe, particularly among people under 50, where stigma and low awareness delay early diagnosis. In response, United EuropeanGastroenterology (UEG) hosted Connecting the Dots: Obesity, Digestive Diseases and Cancers at the European Parliament on 5 June. The event brought together policymakers, clinicians, patient advocates, and public health leaders to push for urgent, coordinated action. 2025-06-30 06:13:54 ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cycles https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare A new international study presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) reveals that IVF cycles involving male partners over the age of 45 carry significantly increased miscarriage risks and lower live birth rates - even when young donor eggs are used. 2025-06-30 06:13:52 Invertir la tendencia de la obesidad, las enfermedades digestivas y el cncer: La UE debe actuar ya https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare BRUSELAS, 30 de junio de 2025 /PRNewswire/ --La obesidad est provocando un fuerte aumento de las enfermedades digestivas y los cnceres en toda Europa, sobre todo entre los menores de 50 aos, donde el estigma y el escaso conocimiento retrasan el diagnstico precoz. En respuesta a esta situacin, United European Gastroenterology (UEG) organiz el 5 de junio en el Parlamento Europeo el evento Connecting the Dots: Obesity, Digestive Diseases and Cancers. El acto reuni a responsables polticos, mdicos, defensores de los pacientes y lderes de la sanidad pblica para impulsar una accin urgente y coordinada. 2025-06-30 06:13:51 41 Reunin Anual de ESHRE: La edad paterna avanzada se relaciona con un mayor riesgo de aborto espontneo https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare 41 Reunin Anual deESHRE: La edad paterna avanzada se relaciona con un mayor riesgo de aborto espontneo y menores tasas de nacidos vivos en ciclos de FIV con vulos de donante 2025-06-30 06:13:50 Renverser le cours des choses en matire d'obsit, de maladies digestives et de cancers : L'UE est invite agir maintenant https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare BRUXELLES, 30 juin 2025 /PRNewswire/ -- L'obsit alimente une forte augmentation des maladies digestives et des cancers en Europe, en particulier chez les personnes de moins de 50 ans, o la stigmatisation et le manque de sensibilisation retardent le diagnostic prcoce. En rponse, United European Gastroenterology (UEG) a organis Connecting the Dots : Obesity, Digestive Diseases and Cancers au Parlement europen le 5 juin. L'vnement a rassembl des dcideurs politiques, des cliniciens, des dfenseurs des patients et des responsables de la sant publique afin d'encourager une action urgente et coordonne. 2025-06-30 06:13:48 ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cycles https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare A new international study presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) reveals that IVF cycles involving male partners over the age of 45 carry significantly increased miscarriage risks and lower live birth rates - even when young donor eggs are used. 2025-06-30 06:13:47 Die Wende im Kampf gegen Fettleibigkeit, Verdauungskrankheiten und Krebserkrankungen: EU muss jetzt handeln https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare BRSSEL, 30. Juni 2025 /PRNewswire/ -- Fettleibigkeit fhrt zu einem starken Anstieg von Verdauungsstrungen und Krebserkrankungen in ganz Europa, insbesondere bei Menschen unter 50 Jahren, wo Stigmatisierung und geringes Bewusstsein eine frhzeitige Diagnose verzgern. Als Reaktion darauf veranstaltete die United EuropeanGastroenterology (UEG) Connecting the Dots: Obesity, Digestive Diseases and Cancers am 5. Juni im Europischen Parlament. Die Veranstaltung brachte politische Entscheidungstrger, Kliniker, Patientenvertreter und fhrende Persnlichkeiten des ffentlichen Gesundheitswesens zusammen, um dringende, koordinierte Manahmen zu fordern. 2025-06-30 06:13:46 ESHRE 41st Annual Meeting: lteres Alter des Vaters mit hherem Fehlgeburtsrisiko und niedrigeren Lebendgeburtenraten bei IVF-Zyklen mit Spendereiern verbunden https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) vorgestellt wurde, zeigt, dass IVF-Zyklen mit mnnlichen Partnern ber 45 Jahren ein deutlich erhhtes Risiko fr Fehlgeburten und niedrigere Lebendgeburtenraten aufweisen - selbst wenn junge Spendereier verwendet werden. 2025-06-30 06:13:44 ESHRE 41st Annual Meeting: L'ge paternel plus lev est li un risque de fausse couche plus important et des taux de naissance vivante plus faibles dans les cycles de FIV avec don d'ovules https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Une nouvelle tude internationale prsente aujourd'hui lors de la 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) rvle que les cycles de FIV impliquant des partenaires masculins gs de plus de 45 ans prsentent des risques de fausses couches nettement plus levs et des taux de naissances vivantes plus faibles, mme lorsque des ovules de jeunes donneuses sont utiliss. 2025-06-30 06:13:43 Innovent Biologics Showcases "Dual Innovations" at Oncology R&amp;D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader. The event drew over 500 participants, including leading oncology key opinion leaders (KOLs), principal investigators, analysts, and global investors, signaling strong engagement with Innovent's transformative vision for the future of oncology. 2025-06-30 06:13:20 PAP Devices Market to Reach $6.97 Billion by 2032, Growing at a CAGR of 5.2% from 2025, Says Meticulous Research https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Market Growth Driven by Rising Respiratory and Sleep Disorders, Aging Population, Advanced Device Technologies, and Expanding Home Healthcare Adoption 2025-06-30 06:13:14 Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). 2025-06-30 06:13:10 - Climate Challenge (, ) https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare - - 2025-06-30 06:10:06 V Pari sa spene uskutonilo informan podujatie Climate Challenge (Hainan Baoting) Europe https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare - Budovanie spoluprce medzi nou a Eurpou na ceste k zelenej a nzkouhlkovej budcnosti 2025-06-30 06:10:02 Fosun International Garners Five Awards from Corporate Governance Asia https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International win Asia's Best CEO from Corporate Governance Asia 2025-06-30 06:09:33 Medical Device Contract Manufacturing Market to Reach $171.19 Billion by 2032, Growing at a CAGR of 9.9% from 2025, Says Meticulous Research https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Market Growth Driven by Outsourcing Preferences, Advanced Manufacturing Technologies, Regulatory Compliance Expertise, and Industry 4.0 Integration 2025-06-30 06:05:37 Coway lance l'Airmega 50, son purificateur d'air cylindrique le plus compact ce jour https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare AMSTERDAM, 30 juin 2025 /PRNewswire/ -- Coway, leader sud-coren des technologies du bien-tre, a lanc sur le march europen l'Airmega 50, le modle le plus compact de sa gamme de purificateurs d'air ce jour. Ce tout nouveau modle fournit une purification de l'air haut de gamme dans les espaces quotidiens en mettant l'accent sur la portabilit, la performance et la tranquillit d'esprit. 2025-06-30 06:05:34 Coway bringt den Airmega 50 auf den Markt, seinen bisher kompaktesten zylindrischen Luftreiniger https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare AMSTERDAM, 27. Juni 2025 /PRNewswire/ -- Coway, Sdkoreas fhrendes Wellness-Tech-Unternehmen, hat den Airmega 50, das bisher kompakteste Modell seiner Luftreiniger-Reihe, auf dem europischen Markt eingefhrt. Diese neueste Version bringt erstklassige Luftreinigung in alltgliche Rume mit dem Schwerpunkt auf Tragbarkeit, Leistung und Seelenfrieden. 2025-06-30 06:05:27 Coway lanceert de Airmega 50, de meest compacte cilindervormige luchtzuiveraar tot nu toe https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare AMSTERDAM, 30 juni 2025 /PRNewswire/ -- Coway, het toonaangevende Zuid-Koreaanse bedrijf op gebied van wellness-technologie, lanceert de Airmega 50, het meest compacte model in het assortiment luchtzuiveraars tot nu toe, op de Europese markt. Deze nieuwste versie brengt luchtzuivering van topniveau in alledaagse ruimtes met aandacht voor draagbaarheid, prestaties en gemoedsrust. 2025-06-30 06:05:20 XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare CAMBRIDGE, Mass., June 29, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced an expansion of its researchcollaboration with Pfizer to pioneer a next-generation molecular modeling platform for drug discovery. This initiative is focused on improving the accuracy of advanced physics-based methods with the speed, scalability, and expansive coverage of cutting-edge AI models to optimize the discovery and development of small molecule medicines. Building on the success of their existing strategic collaboration, Pfizer and XtalPi will now collaborate on the development of an enhanced platform to grasp Pfizer's rapidly expanding small molecule chemical space, with the goal of delivering accurate predictive tools with significantly improved throughput. 2025-06-30 06:05:16 YUTIQ Sees Continued Market Growth in Treatment of Chronic Non-Infectious Uveitis | DelveInsight https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare YUTIQ addresses a significant unmet need in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The uveitis treatment market is projected to grow steadily, driven by rising incidence and improved diagnosis, positioning YUTIQ for strong market adoption. 2025-05-07 05:18:14 WST INVESTOR ALERT: West Pharmaceutical Services, Inc. Investors with Substantial Losses Have Opportunity to Lead the West Pharmaceutical Class Action Lawsuit https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SAN DIEGO, May 6, 2025 /PRNewswire/ --Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the "Class Period"), have until July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutical class action lawsuit charges West Pharmaceutical and certain of West Pharmaceutical's current and former top executives with violations of the Securities Exchange Act of 1934. 2025-05-07 05:18:10 Waters intgre des dtecteurs de diffusion de lumire multi-angles au logiciel Empower afin d'amliorer le contrle de la qualit des produits biologiques et simplifier la conformit rglementaire. https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Rsum de l'actualit 2025-05-07 05:18:07 Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare LEXINGTON, Mass., May 6, 2025 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy to purchase 200,000 shares of Curis common stock, with a grant date of May 1, 2025 (the "Inducement Grant"). 2025-05-07 05:18:02 Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery. Clobetasol propionate ophthalmic suspension, 0.05% (APP13007) was approved by the U.S. Food and Drug Administration (FDA) in 2024. APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT nanoparticle formulation platform. The novel formulation enables a convenient and straightforward dosing regimen, while providing rapid and sustained relief of inflammation and pain, which in Phase 3 trials proved statistically and clinically superior to its matching placebo (p<0.001). 2025-05-07 05:17:52 The Independence Fund Brings Veterans' Voices to D.C. for MAY 6 VA Hearing https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare WASHINGTON, May 6, 2025 /PRNewswire/ -- The Independence Fund, a national non-profit organization dedicated to serving the needs of catastrophically wounded Veterans and their families, was honored to join six of our nation's Veterans at today's Senate Committee on Veterans' Affairs hearing, "Veterans at the Forefront: Secretary Collins on the Future at VA." 2025-05-07 05:17:48 Adcentrx Therapeutics Granted Fast Track Designation for ADRX-0706 Nectin-4 ADC for the Treatment of Advanced Cervical Cancer https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SAN DIEGO, May 6, 2025 /PRNewswire/ -- Adcentrx Therapeutics("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program, ADRX-0706, for the treatment of patients with locally advanced or metastatic squamous cell cervical cancer. 2025-05-07 05:17:43 Veltex Corporation Announces Leadership Changes and Strategic Board Expansion https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare CHICAGO, May 6, 2025 /PRNewswire/ -- Veltex Corporation (OTCQB: VLXC), a premier Health and Wellness Acquisition Firm, is pleased to announce key enhancements to its leadership structure as part of its continued growth strategy and mission to serve communities impacted by substance use disorder. 2025-05-07 05:17:39 Dr. Austin Harris Champions Student Athletes with Prestigious Grant https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare LOS ANGELES, May 6, 2025 /PRNewswire/ -- Dr. Austin Harris, Dr. Austin Harris, MD, founder of NeuroRelief Ketamine & Infusion Therapy, offers a $1,000 grant to support student athletes balancing academics and sports. This scholarship is open to undergraduates at accredited U.S. colleges who show dedication both on the field and in the classroom. 2025-05-07 05:17:34 Dr. Zachary Lipman Launches Scholarship to Support Student Athletes Pursuing Careers in Sports https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare CHICO, Calif., May 6, 2025 /PRNewswire/ -- Dr. ZacharyLipman, a dedicated physician and advocate for well-being, is pleased to announce the establishment of the Dr. Zachary Lipman Scholarship for Student Athletes. This one-time award of $1,000 aims to provide financial assistance to undergraduate students who actively participate in athletics and demonstrate a clear intention to pursue a career within the sports field. 2025-05-07 05:17:33 CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SUZHOU, China, May 6, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC), key assets in CStone Pipeline 2.0, have been delivered at the 2025 American Association for Cancer Research (AACR) Annual Meeting. 2025-05-07 05:17:29 Discover the Power of Community as the ALS Network Highlights Care Services, Advocacy, and Research during ALS Awareness Month https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare LOS ANGELES, May 6, 2025 /PRNewswire/ --May isALS Awareness Month, and the ALS Network is committed to raising awareness and understanding of the devastating disease that has no known cure. This month, we highlight the power of community and invite everyone to explore the many ways to get involved, give back, and learn more. 2025-05-07 05:17:20 Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc. https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare TOKYO, May 7, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint research* with RIBOMIC Inc. (President: Yoshikazu Nakamura, Headquarters: Minato-ku, Tokyo, hereinafter referred to as "RIBOMIC"), a drug discovery startup focused on the development and production of aptamer pharmaceuticals, on the development of technology for controlling the pharmacokinetics of nucleic acid aptamers using the antibody-drug conjugate (ADC) manufacturing technology "AJICAP" (hereinafter referred to as "AJICAP"). As a result of this research, RIBOMIC has successfully extended the half-life of a conjugate of nucleic acid aptamers and the Fc region of immunoglobulins in the bloodstream. 2025-05-07 05:15:53 Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc. https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare TOKYO, May 6, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint research* with RIBOMIC Inc. (President: Yoshikazu Nakamura, Headquarters: Minato-ku, Tokyo, hereinafter referred to as "RIBOMIC"), a drug discovery startup focused on the development and production of aptamer pharmaceuticals, on the development of technology for controlling the pharmacokinetics of nucleic acid aptamers using the antibody-drug conjugate (ADC) manufacturing technology "AJICAP" (hereinafter referred to as "AJICAP"). As a result of this research, RIBOMIC has successfully extended the half-life of a conjugate of nucleic acid aptamers and the Fc region of immunoglobulins in the bloodstream. 2025-05-07 05:15:51 La Maison de l'Espoir de Gedeon Richter ouvre ses portes pour venir en aide 300 femmes par an Bamako, en Afrique https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare BUDAPEST, Hongrie, 7 mai 2025 /PRNewswire/ -- Un centre offrant un soutien mdical et ducatif ainsi qu'un abri aux femmes vulnrables a t construit Bamako, la capitale du Mali, grce l'aide financire de Gedeon Richter. En tant que l'un des principaux fabricants mondiaux de mdicaments pour la sant des femmes, Richter souligne l'importance de promouvoir la sant et la qualit de vie des femmes dans tous les pays o il opre. Avec ce nouveau centre, en mesure d'accueillir des dizaines de femmes dfavorises de la rgion, Richter a pour objectif de venir en aide prs de 300 femmes par an. Cette initiative n'est pas un simple investissement ponctuel, car l'entreprise pharmaceutique s'est engage soutenir long terme le fonctionnement de la Maison de l'Espoir. 2025-05-07 05:15:05 "Gedeon Richter House of Hope" abre sus puertas para apoyar a 300 mujeres anualmente en frica-Bamako https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare BUDAPEST, Hungra, 7 de mayo de 2025 /PRNewswire/ -- En Bamako, capital de Mali, se ha construido un centro que ofrece atencin mdica, apoyo educativo y albergue para mujeres vulnerables, con la ayuda financiera de Gedeon Richter. Como uno de los principales fabricantes mundiales de medicamentos para la salud femenina, Richter enfatiza la importancia de promover la salud y la calidad de vida de las mujeres en todos los pases donde opera. Con el nuevo centro, capaz de albergar a decenas de mujeres desfavorecidas de la regin, Richter aspira a brindar ayuda a casi 300 mujeres al ao. Esta iniciativa no es una inversin puntual, ya que la compaa farmacutica se compromete a apoyar a largo plazo el funcionamiento del centro House of Hope. 2025-05-07 05:14:59 Caplight Awarded Patent for AI-Powered Pricing Feed To Improve Private Market Transparency https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SAN FRANCISCO, May 6, 2025 /PRNewswire/ -- Caplight Technologies, an innovator in private market data and trading infrastructure, today announced the issuance of a patent by the United States Patent and Trademark Office protecting Caplight's proprietary method for estimating private company stock prices using secondary market transaction data. 2025-05-07 05:09:29 Grant Industries Selects Labbit LIMS to Drive Digital Transformation Across Its Regulated Labs https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Labbit's graph-based architecture supports the unique needs of Grant's different lab environments while unifying data to deliver full traceability for quality assurance and regulatory compliance. 2025-05-07 05:09:08 Families Turn to Experts as Dementia Cases Rise https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare More than half of Aging Life Care Managers' clients are living with dementia, a new national survey finds. 2025-05-01 09:22:49 Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Seven months after the FDA approved the reintroduction of Roche's eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary cause of blindness related to diabetes. This marks the second approved indication for Susvimo, which was initially cleared in October 2021 as an alternative to frequent eye injections for wet age-related macular degeneration. 2025-05-01 09:22:45 ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare PLAINSBORO, N.J., April 30, 2025 /PRNewswire/ -- Today, The New England Journal of Medicine(NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which investigated the effects of once-weekly subcutaneous semaglutide 2.4 mg on liver histology compared to placebo at 72 weeks in adults with MASH and moderate to advanced liver fibrosis (stage 2 or 3). At Week 72, the first primary endpoint showed 62.9% of people treated with semaglutide 2.4 mg achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% on placebo with estimated difference in responder proportions (EDP) of 28.7% (95% CI, 21.1 to 36.2; P<0.001). For the second primary endpoint at Week 72, 36.8% of people treated with semaglutide 2.4 mg achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% on placebo (EDP, 14.4%; 95% CI, 7.5 to 21.3; P<0.001).1 2025-05-01 09:22:42 WILLOW BIOSCIENCES INC. ANNOUNCES COMPLETION OF SALE OF OPERATING SUBSIDIARY AND MANAGEMENT CHANGES https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare CALGARY, AB, April 30, 2025 /PRNewswire/ -Willow Biosciences Inc. (the "Company") (TSX:WLLW) (OTCQB: CANSF) announces the completion today of the sale (the "Transaction") of its wholly-owned operating subsidiary, Epimeron USA, Inc., to the U.S. subsidiary of Mycofeast Ltd., a privately-held, arms-length entity based in the United Kingdom (the "Purchaser"), pursuant to the terms of a share purchase agreement dated March 14, 2025 (the "Share Purchase Agreement"), between the Company and the Purchaser. 2025-05-01 09:22:34 RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare FREDERICK, Md., April 30, 2025 /PRNewswire/ -- RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science. This collaboration aims to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionize the treatment of degenerative disease. 2025-05-01 09:22:32 NEW ONLINE TOOL HELPS TEENS TAKE CHARGE OF THEIR MENTAL HEALTH https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare YMCA Launches Interactive Teen Mental Health Resource Hub for Mental Health Awareness Month 2025-05-01 09:22:29 BayCare Breaks Ground on BayCare Hospital Manatee and BayCare HealthHub (Manatee) https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare PALMETTO, Fla., April 30, 2025 /PRNewswire/ -- BayCare, the leading health care system in West Central Florida, broke ground today on BayCare Hospital Manatee, its 17th hospital, and BayCare HealthHub(Manatee). This milestone marks a significant step in expanding access to health care for the growing Manatee County community. The hospital will be the county's first not-for-profit hospital and the only hospital north of the Manatee River. 2025-05-01 09:22:22 Genomma Lab Internacional Announces Results for the First Quarter 2025 https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare MEXICO CITY, April 30, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2025. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise mentioned. 2025-05-01 09:22:15 Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare DURHAM, N.C., April 30, 2025 /PRNewswire/ --Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi(dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101. 2025-05-01 09:22:14 PHARMA AI COUNCIL (PAC) STARTET ZUR BESCHLEUNIGUNG DER INNOVATION UND DES VERANTWORTUNGSVOLLEN EINSATZES DER KOGNITIVEN TECHNIK IN DEN BIOWISSENSCHAFTEN https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Experten der Pharmaindustrie kommen zusammen, um die Zukunft der KI mitzugestalten 2025-05-01 09:22:11 Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Blue Earth Therapeutics (PRNewsfoto/Blue Earth Therapeutics Ltd) 2025-05-01 09:22:08 S&amp;E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SEOUL, South Korea, May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical trial of its investigational stroke therapy, SNE-101. This is the first exosome-based therapy in Korea to enter clinical trials, marking a major milestone in the country's biopharmaceutical landscape. 2025-05-01 09:21:21 Save the Storks Celebrates Superhero Moms and Brave Choices for Mother's Day 2025 https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare The national non-profit organization recognizes how superhero moms like Chelsea Noble Cameron shape generations, recognizing birth moms, adoptive moms and foster moms. 2025-05-01 09:21:14 Doceree welcomes Karima Sharif as SVP - Strategic Accounts, to strengthen global client partnerships https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare The industry veteran brings over 25 years of healthcare marketing expertise in accelerating growth and value for leading pharmaceutical brands 2025-05-01 09:21:05 Saddleback Medical Center Achieves Eighth National "A" Safety Grade from Leapfrog https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare LAGUNA HILLS, Calif., May 1, 2025 /PRNewswire/ -- MemorialCare Saddleback Medical Centerhas earned an "A" Hospital Safety Grade from The Leapfrog Group, a national nonprofit watchdog that sets rigorous standards for excellence in patient care. This marks the eighth time Saddleback Medical Center has received an "A" grade, recognizing Saddleback Medical Center's achievements in protecting patients from preventable harm and error in the hospital. 2025-05-01 09:19:27 Joseph Spine Institute Announces New Location in St. Petersburg, Florida - Founder Dr. Samuel Joseph, Jr. to See Patients at New Location https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare ST. PETERSBURG, Fla., May 1, 2025 /PRNewswire/ -- Joseph Spine Institute, a leading provider of advanced spine care in Florida, is proud to announce the opening of its newest clinic location in St. Petersburg. This expansion marks another milestone in the institute's commitment to offering state-of-the-art, patient-centered spine care across the region. 2025-05-01 09:19:19 OsteoCentric Technologies Announces Formation of UnifiMI Industrial Companies https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare AUSTIN, Texas, May 1, 2025 /PRNewswire/ -- OsteoCentric Technologies, a global leader in innovative fastener technologies, announced the creation of seven wholly-owned subsidiaries dedicated to penetrating key industrial market segments including Aerospace & Defense, Transportation, Construction, Oil & Gas, Automotive, Agriculture, and Sporting Goods. This strategic move leverages the company's proprietary UnifiMI Fastener Technology to address some of the most critical challenges, across the most demanding industrial applications. 2025-05-01 09:13:21 Systech celebra 40 aos de excelencia en empaquetado y serializacin en la conferencia CDMO Live https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Para conmemorar cuatro dcadas de innovacin, Systech ofrece una plataforma nica para CDMO que elimina los dolores de cabeza que generan mltiples proveedores y brinda visibilidad, desde la lnea de envasado hasta el cliente. 2025-05-01 09:13:12 Systech Celebrates 40 Years of Packaging and Serialization Excellence at CDMO Live Conference https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare Marking four decades of innovation, Systech delivers a single platform to CDMOs that eliminates multi-vendor headaches and delivers visibility-from the packaging line to customer. 2025-05-01 09:13:02 Doceree welcomes Karima Sharif as SVP - Strategic Accounts, to strengthen global client partnerships https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare The industry veteran brings over 25 years of healthcare marketing expertise in accelerating growth and value for leading pharmaceutical brands 2025-05-01 09:12:29 New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt PFA System for Patients with AFib https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare ABBOTT PARK, Ill., April 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) has announced new data from its VoltCE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volt PFA System for the treatment of atrial fibrillation (AFib). The data also highlights the excellent safety profile of the Volt PFA System alongside the system's ability to achieve results with fewer therapy applications (just 4.7 applications per vein on average) than on-market competitive PFA systems. 2025-04-28 07:32:53 Medtronic Affera pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare GALWAY, Ireland and SAN DIEGO, April 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera family of technologies, including the next-generation Sphere-360 single-shot pulsed field ablation (PFA) catheter and the groundbreaking Sphere-9 combination mapping and dual-energy focal PFA catheter. Data were presented in High Impact Science Sessions at the Heart Rhythm Society 2025 Annual Meeting in San Diego; the Sphere-360 study was simultaneously published in the Heart Rhythm Journal. 2025-04-28 07:32:49 Bestzyme's Mellia Brazzein Receives FDA "No Questions" Letter, Bringing Creative Sugar Reduction Solution to Global Market https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare PISCATAWAY, N.J., April 26, 2025 /PRNewswire/ --Bestzyme is pleased to announce a flagship product Mellia Brazzein, has officially received the "No Questions" letter from the U.S. Food and Drug Administration (FDA) regarding its GRAS (Generally Recognized as Safe) status. The GRAS designation recognizes it as general-purpose sweetener for a wide range of applications in the food and beverage industry. 2025-04-28 07:32:47 Keymed Biosciences annonce l'autorisation du CM518D1 comme nouveau mdicament de recherche par l'Administration nationale des produits mdicaux de Chine pour le traitement des tumeurs solides https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare CHENGDU, Chine, 27 avril 2025 /PRNewswire/ -- Keymed BiosciencesInc. (HKEX: 02162) (Keymed ou la socit) a rcemment annonc que le CM518D1, un conjugu anticorps-mdicament (ADC) ciblant la CDH17 et mis au point par Keymed, a t autoris comme nouveau mdicament de recherche par le Centre d'valuation des mdicaments de l'Administration nationale des produits mdicaux et fait actuellement l'objet d'essais cliniques de phasesI/II en Chine pour le traitement de tumeurs solides. Cette tape marque une nouvelle avance dans le dveloppement des mdicamentsADC de Keymed, qui renforce ainsi son pipeline thrapeutique innovant dans le domaine de l'oncologie. 2025-04-28 07:32:45 Keymed Biosciences gibt die IND-Genehmigung fr CM518D1 durch die National Medical Products Administration of China zur Behandlung von Solide Tumoren bekannt https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare CHENGDU, China, 27. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) (Keymed" oder das Unternehmen") gab vor kurzem bekannt, dass CM518D1, ein von Keymed entwickeltes Antikrper-Wirkstoff-Konjugat (ADC), das auf CDH17 abzielt, vom Center for Drug Evaluation (CDE) der National Medical Products Administration (NMPA) die Zulassung fr ein neues Prfprparat (IND) erhalten hat und derzeit in China in klinischen Studien der Phase I/II zur Behandlung von soliden Tumoren getestet wird. Dieser Meilenstein markiert einen weiteren Durchbruch in Keymeds ADC Medikamentenentwicklung und strkt die innovative therapeutische Pipeline in der Onkologie. 2025-04-28 07:32:43 Keymed Biosciences anuncia la aprobacin de CM518D1 para el tratamiento de tumores slidos https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare CHENGDU, China, 27 de abril de 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" o la "compaa") anunci recientemente que CM518D1, un conjugado anticuerpo-frmaco (ADC) dirigido a CDH17 desarrollado por Keymed, recibi la aprobacin como Nuevo Medicamento en Investigacin (IND) del Centro de Evaluacin de Medicamentos (CDE) de la Administracin Nacional de Productos Mdicos (NMPA), y actualmente se encuentra en ensayos clnicos de Fase I/II en China para el tratamiento de tumores slidos. Este hito marca un nuevo avance en el desarrollo de frmacos ADC de Keymed, fortaleciendo an ms su innovadora cartera de productos teraputicos en oncologa. 2025-04-28 07:32:42 Abbott Highlights New AVEIR Data, Initiates Trial for the Company's Conduction System Pacing Technology https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SAN DIEGO, April 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from theAVEIR Conduction System Pacing (CSP) acute clinical feasibility study, which demonstrated the safety and performance of the investigational AVEIR CSP leadless pacemaker technology. The AVEIR CSP acute clinical feasibility study is the world's first assessment of a leadless pacemaker delivering conduction pacing to the heart's left bundle branch (LBB) area.CSP is a novel pacing approach that targets the LBB area by enabling pacing that mimics the heart's natural electrical rhythm. 2025-04-28 07:32:40 Marc Dubrick, Grace Alexander Win St. Anthony's Triathlon https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare More than 3,100 athletes swim, bike and run through downtown St. Petersburg as Dubrick wins second year in a row 2025-04-28 07:32:36 Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025 https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare CAMBRIDGE, Mass., April 27, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integratedsolutionsfrom "Idea to IND" (I to ITM), today announcedthat its partner, Pfizer, has presented preclinical data onPF-08052666 (HBM9033; SGN-MesoC2), afirst-in-class topoisomerase 1 inhibitor (TOP1i)-based antibody-drug conjugate (ADC) targeting mesothelin (MSLN), at the AACR Annual Meeting 2025. This ADC was originally developed using Nona Biosciences' proprietary Harbour Miceand integrated ADC platforms. Pfizer acquired its global clinical development and commercialization rights on December 14, 2023. 2025-04-28 07:32:23 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SAN FRANCISCO and SUZHOU, China, April 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies, tri-specific antibodies as well as bispecific antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR meeting will take place April 25-30, 2025, in Chicago, Illinois. 2025-04-28 07:32:21 ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery at 2025 AACR Annual Meeting https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SUZHOU, China, April 27, 2025 /PRNewswire/ -- From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-C5252 targeting malignant glioma through poster presentation at American Association for Cancer Research ("AACR") annual meeting. 2025-04-28 07:32:19 2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1 https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SHANGHAI, April 27, 2025 /PRNewswire/ --Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results were shared for ABSK112 (EGFR exon20ins inhibitor), ABSK131 (PRMT5*MTA inhibitor), and ABK-KRAS-1 (pan-KRAS inhibitor), as well as results from a study investigating potential resistance mechanisms to KRAS G12C inhibitors. 2025-04-28 07:32:16 OMRON Healthcare dona 4.000 monitores de presin arterial y avanza en la deteccin de fibrilacin auricular https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare - OMRON Healthcare dona 4.000 monitores de presin arterial y avanza en la deteccin de fibrilacin auricular con tecnologa Intellisense AFib basada en IA 2025-04-28 07:32:14 OMRON Healthcare spendet 4.000 Blutdruckmessgerte und verbessert AFib-Screening mit AI-basierter Intellisense AFib-Technologie https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare -Intellisense AFib-Technologie erkennt bei jeder Messung mgliches Vorhofflimmern; der 17. Mai ist Welt-Blutdrucktag im, dem Monat der Blutdruckmessung -May Measurement Month - 2025-04-28 07:32:12 Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare OSLO, Norway, April 28, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The trial was closed for recruitment at the end of 2023 and patients are currently in long-term follow-up. 2025-04-28 07:32:09 Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare OSLO, Norway, April 28, 2025 /PRNewswire/ -- In connection with the release of the first quarter 2025 company update,Oncoinvent invites for a Live streamed of quarterly presentation in English on Wednesday 30thof April at 11.00 AM CEST. A webcast will be available for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar. 2025-04-28 07:32:07 YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare SHANGHAI, April 28, 2025 /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stagein vivogene editing company committed to pioneering the next generation of precision genetic medicines, announced promising interim clinical data from an investigator-initiated trial (IIT) of YOLT-101 (NCT06458010), and the data has been published on medRxiv. YOLT-101 is an investigationalin vivobase editing therapy for the treatment of heterozygous familial hypercholesterolemia (HeFH). Clinical data demonstrate that YOLT-101 can safely and effectively reduce low-density lipoprotein cholesterol (LDL-C) levels in HeFH patients with a single administration. As a next-generation gene-editing therapy, YOLT-101 represents a breakthrough in lipid-lowering treatment - moving beyond daily pills and regular injections, and opening a new era of "one-time treatment for lifelong LDL-C reduction." 2025-04-28 07:27:09 ILIKOS Consulting Group Accelerates International Growth with New Greek Subsidiary https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare PAPHOS, Cyprus, April 28, 2025 /PRNewswire/ -- ILIKOS Consulting Group, a leader in commercial strategy, BD and corporate development solutions for Contract Research Organizations (CROs) and life-science companies proudly announces the launch of its new subsidiary in Greece. This strategic move underscores the company's commitment to expanding its international footprint and enhancing its portfolio of business solutions. 2025-04-28 07:26:49 Annonce de publication d'un article : EditForce dmontre l'efficacit du traitement de la dystrophie myotonique de type 1 grce la technologie de plateforme PPR https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare FUKUOKA, Japon, 28 avril 2025 /PRNewswire/ -- EditForce, Inc. (Sige social: Fukuoka, Japon) a le plaisir d'annoncer qu'un article de recherche sur les rsultats d'une tude conjointe avec le groupe de recherche dirig par le professeur Masayuki Nakamori du dpartement de neurologie de l'cole suprieure de mdecine de l'Universit de Yamaguchi, et le professeur Hideki Mochizuki du dpartement de neurologie de l'cole suprieure de mdecine de l'Universit d'Osaka, a t publi dans Science Translational Medicine le 16 avril 2025 (heure avance de l'Est). 2025-04-28 07:22:14 Introducing the New Carbonhand: Smarter and More Supportive Than Ever https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare STOCKHOLM, April 28, 2025 /PRNewswire/ -- Bioservo is excited to unveil the latest innovation in grip-strengthening technology, the New Carbonhand glove. This advanced glove features several enhancements and is designed to support different types of grips to make everyday tasks easier and more accessible. This also means that more people can benefit from Carbonhand. 2025-04-28 07:16:11 Nike: Ehemaliger Vizeprsident und Geschftsleiter Bert Hoyt wird Vorstandsberater bei dBio und treibt die Entwicklung der nchsten Generation von Sport- und Gesundheitstechnologien voran https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare LUXEMBURG, 24. April 2025 /PRNewswire/ -- Die Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), ein fhrender Innovator im Bereich Sport- und Gesundheitstechnologie, der fortschrittliche tragbare AIoT-Lsungen anbietet, die die berwachung der sportlichen Leistung nahtlos mit Echtzeit-Gesundheitsdaten verbinden, freut sich, Hubertus Bert" Hoyt als neuesten Berater des Vorstands bekannt zu geben. 2025-04-24 08:22:58 Former Nike VP &amp; GM Bert Hoyt Joins dBio to Drive Next-Gen Sports &amp; Health Tech as Board Advisor https://releases.worldpressplatform.com/healthcare https://releases.worldpressplatform.com/healthcare LUXEMBOURG, April 23, 2025 /PRNewswire/ -- Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), a leading innovator in sports and health tech, delivering advanced wearable AIoT solutions that seamlessly merge athletic performance monitoring with real-time health insights, is pleased to announce Hubertus "Bert" Hoyt as its newest Board Advisor. 2025-04-24 08:22:52